24 May 2019
Fevertree Drinks plc
("Fever-Tree" or the "Group")
Bill Ronald, Chairman of Fever-Tree, the world's leading supplier of premium carbonated mixers, will make the following statement at the Group's Annual General Meeting to be held at 11.30am today.
"2018 was a year of significant progress for Fever-Tree. The Group reinforced its market leading position in the UK, successfully established its own operations in the US and the business made real progress across Europe.
The beginning of 2019 has seen further encouraging operational progress across our key international regions as the Group continues to invest in widening and deepening its distribution networks. Whilst we are mindful of last year's exceptional summer trading performance in the UK, we remain confident in achieving Board expectations for the full year ending 31 December 2019."
For further information:
Fevertree Drinks plc +44 (0)20 7349 4922
Tim Warrillow, Co-founder and CEO
Andy Branchflower, Finance Director
Oliver Winters, Communications & IR Director
Numis Securities - Nominated Adviser and Joint Broker +44 (0)20 7260 1000
Investec Bank plc - Joint Broker +44 (0)20 7597 5970
Brunswick Group +44 (0) 20 7404 5959
Notes to Editors:
Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 70 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On-Trade") as well as selected retail outlets ("Off-Trade").
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.